Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.59 |
| ▸ | BCR | P11274 | 4/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.56 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 4/20 | 0.56 |
| ▸ | CSF1R | P07333 | 3/20 | 0.56 |
| ▸ | BMX | P51813 | 2/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | KIT | P10721 | 3/20 | 0.55 |
| ▸ | TEK | Q02763 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945922 | 0.91 | BRAF (0.59) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945905 | 0.91 | BTK (0.58) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941616 | 0.89 | KIT (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2941258 | 0.89 | ABL1 (0.55) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2940107 | 0.89 | KDR (0.57) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2945359 | 0.88 | ABL1 (0.70) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2942477 | 0.88 | BRAF (0.61) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL2946486 | 0.88 | ABL1 (0.59) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1408815 | 0.88 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL30899721 | 0.88 | ABL1 (0.67) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-1635835-B1 | 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | NOVARTIS AG (CH) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293340-A1 | 2-Aminopyrimidine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | ABL1 72/4885PDGFRA 881/4885BCR 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.